J Pediatr Gastroenterol Nutr. 2023 Aug 1;77(2):235-239.doi: 10.1097/MPG.0000000000003838. Epub 2023 May 23.

Laura Gianolio ¹, Katherine Armstrong ¹, Ewan Swann ², Rhona Shepherd ¹, Paul Henderson ^1 3, David C Wilson ^1 3, Richard K Russell ^1 3

Author information

¹From the Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children and Young People, Edinburgh, UK.

²Paediatric Specialist Pharmacist, Royal Hospital for Children and Young People, Edinburgh, UK.

³Child Life and Health, University of Edinburgh, Edinburgh, UK.

Abstract

No real-world data are available on subcutaneous infliximab (SC-IFX) in pediatric inflammatory bowel disease (PIBD). We report a single-center cohort experience of an elective switching program from biosimilar intravenous infliximab to SC-IFX, 120 mg fortnightly, as maintenance. Clinical and laboratory data were collected for 7 patients with infliximab trough levels collected prior and at 6 and 40 weeks after the switch. High treatment persistence was registered with a single patient discontinuing the treatment due to high IFX antibodies, already present before switching. All patients remained in clinical remission with no significant changes in laboratory markers and median infliximab trough levels (12.3 µg/mL at baseline; 13.9 and 14.0 µg/mL at 6 and 40 weeks respectively). No newly-developed IFX antibodies were detected and no adverse reactions or rescue therapies were recorded. Our real-world data support the feasibility of an elective switch to SC-IFX in PIBD as maintenance with potential advantages concerning medical resources and patient satisfaction.